ATLANTA, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether aTyr Pharma, Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR) complied with federal securities laws. On September 15, 2025, aTyr announced topline results from its Phase 3 EFZO-FIT study, which “did not meet its primary endpoint of change from baseline in mean daily oral corticosteroid (“OCS”) dose at week 48.” Following this news, the price of the Company’s stock declined. If you purchased aTyr stock and suffered a loss ...

Seeking Alpha's transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage. The purpose of this profile is to allow us to share with our readers new transcript-related developments. Thanks, SA Transcripts Team ...

RBC Capital downgraded aTyr Pharma to "Sector Perform" from "Outperform" following the Phase III EFZO-FIT study results of Efzofitimod.The stock experienced a significant decrease of 83.17%, reflecting investor reactions to the study outcomes and the downgrade.aTyr Pharma's market capitalization stands at approximately $99.46 million, highlighting the volatility and challenges in the biotech sector, especially for companies focusing on rare diseases.aTyr Pharma, Inc. (NASDAQ:ATYR) is a biotechnology company ...

Derek Archila from Wells Fargo set a price target of $1 for aTyr Pharma, Inc. (NASDAQ:ATYR), indicating a cautious outlook.The announcement of the Phase III EFZO-FIT study results for Efzofitimod in pulmonary sarcoidosis marks a significant milestone for the company.aTyr Pharma's stock has experienced a dramatic decrease of 83.17%, highlighting the volatility and challenges in the biotech sector.aTyr Pharma, Inc. (NASDAQ:ATYR) is a biotechnology company focused on developing innovative medicines for patient ...

股价显著下跌公司 - aTyr Pharma股价从年内高点7.29美元暴跌82.67%至1.04美元 交易量激增至1.25亿股[2][8] - Kindly MD股价从34.77美元下跌53.24%至1.3美元 交易量达8,491万股[3][8] - Syra Health股价从0.94美元下跌40%至0.057美元[4][8] - Wearable Devices股价下跌39.57%至2.84美元 交易量12,217股[5] - Longevity Health股价下跌42.24%至1.34美元[6] 公司特定动态 - aTyr Pharma专注于新型免疫通路药物开发但缺乏分析师关注[2] - Kindly MD获纳斯达克期权市场交易批准[3] - Syra Health第二季度收入190万美元与去年持平 人口健康部门增长197% 毛利率提升2,090个基点至38.7% 每股收益从-0.21美元改善至-0.01美元[4] - Wearable Devices致力于非侵入性神经输入接口技术开发[5] - Longevity Health与血浆采集龙头企业True Health达成最终合并协议[6] 市场活动特征 - 高交易量公司包括aTyr Pharma(1.25亿股)和Kindly MD(8,491万股)显示市场关注度集中[2][3] - 股价波动受临床试验结果、财务报告、监管新闻和市场动态多重因素影响[7]

美股市场表现 - 道琼斯指数上涨0.06%至45,856.77点 纳斯达克指数上涨0.75%至22,307.16点 标普500指数上涨0.37%至6,608.41点 [1] - 非必需消费品板块领涨1.9% 医疗保健板块下跌0.5% [1] 个股异动情况 - Check-Cap Ltd股价暴涨261%至2.68美元 公司与MBody AI达成最终合并协议 [9] - Helius Medical Technologies股价飙升161%至19.70美元 公司宣布启动12.5亿美元SOL支持的国库策略 并完成超额认购的PIPE发行 [9] - Robo.ai Inc股价上涨43%至2.0850美元 公司与JW Group及Ferox Investments签署合资协议 在迪拜工业城建立Robo.ai工业城 [9] - aTyr Pharma股价暴跌81%至1.1694美元 公司efzofitimod治疗肺结节病的三期研究未达到主要终点 [9] - Avidity Biosciences股价下跌7%至41.68美元 公司申请发行1500万股普通股 [9] - Hain Celestial Group股价下跌26%至1.5894美元 公司第四季度财务业绩不及预期 [9] 大宗商品表现 - 原油价格上涨1%至63.31美元 黄金价格上涨0.3%至3,698.80美元 [5] - 白银价格下跌0.1%至42.810美元 铜价上涨1%至4.6975美元 [5] 全球市场走势 - 欧洲STOXX 600指数上涨0.47% 西班牙IBEX 35指数上涨0.63% 德国DAX指数上涨0.27% 法国CAC 40指数上涨1.05% 英国富时100指数微跌0.01% [6] - 香港恒生指数上涨0.22% 中国上证综指下跌0.26% 印度BSE Sensex指数下跌0.15% [7] 经济数据 - 纽约联储制造业指数从8月的11.9降至9月的-8.7 远低于市场预期的5 [2][10]

PresentationIt is now my pleasure to hand the conference call over to Ashlee Dunston, aTyr's Senior Director of Investor Relations and Public Affairs. Ms. Dunston, you may begin.Good morning, ladies and gentlemen, and welcome to aTyr Pharma conference call to review the top line results for the Phase III EFZO-FIT study of efzofitimod in pulmonary sarcoidosis. [Operator Instructions] As a reminder, this conference is being recorded for replay purposes.Ashlee DunstonDirector of Investor Relations & Corporate ...

PresentationIt is now my pleasure to hand the conference call over to Ashlee Dunston, aTyr's Senior Director of Investor Relations and Public Affairs. Ms. Dunston, you may begin.Good morning, ladies and gentlemen, and welcome to aTyr Pharma conference call to review the top line results for the Phase III EFZO-FIT study of efzofitimod in pulmonary sarcoidosis. [Operator Instructions] As a reminder, this conference is being recorded for replay purposes.Ashlee DunstonDirector of Investor Relations & Corporate ...

LOS ANGELES--(BUSINESS WIRE)---- $ATYR--aTyr Pharma, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – ATYR. ...

股价表现 - 公司股价单日暴跌82.42%至1.06美元[1][4] - 成交量达3470万股 远超483万股的平均成交量[1] 临床试验结果 - 针对268名肺结节病患者的EFZOFITIMOD三期试验未达到主要终点[1][2] - 由于采用分层评估设计 主要终点未达标导致后续统计结果仅具名义显著性[2] - 药物在3.0 mg/kg和5.0 mg/kg剂量下均表现出良好耐受性[3] 次要疗效指标 - 5.0 mg/kg组平均每日OCS剂量降低至2.79mg 对照组为3.52mg (p=0.3313)[5] - 5.0 mg/kg组完全撤除类固醇患者比例达52.6% 对照组为40.2% (p=0.0919)[5] - KSQ-Lung评分改善10.36分 对照组改善6.19分 (p=0.0479)[5] - 29.5%的5.0 mg/kg组患者实现完全撤除类固醇且KSQ评分改善 对照组仅14.4% (p=0.0199)[5] - 肺功能指标FVC在48周内保持稳定 治疗组变化-1.81% 对照组-2.11% (p=0.7875)[5] 后续计划 - 公司计划与FDA商讨确定潜在监管路径[2][3] - 尽管主要终点未达标 但多项临床相关疗效终点显示药物活性[3]